Evidence map›Paper›PMID 41667846›Full record

ReviewNature reviews. Neurology2026

Bridging global diversity gaps in Parkinson disease research.

Daniel Teixeira-Dos-Santos, Ai-Huey Tan, Njideka Okubadejo, Lorraine V Kalia, Artur F S Schuh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel Teixeira-Dos-SantosGraduate Program in Medical Sciences, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Ai-Huey TanDepartment of Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.ORCID http://orcid.org/0000-0002-2979-3839
Njideka OkubadejoNeurology Unit, Department of Medicine, College of Medicines, University of Lagos, Idi Araba, Nigeria.ORCID http://orcid.org/0000-0003-2975-8803
Lorraine V KaliaEdmond J Safra Program in Parkinson's Disease, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-9384-1305
Artur F S SchuhGraduate Program in Medical Sciences, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. aschuh@hcpa.edu.br.ORCID http://orcid.org/0000-0002-8722-0908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of Parkinson disease (PD) is rapidly shifting towards low-income and middle-income countries (LMICs), which already account for 44% of all individuals with PD. Despite this trend, the populations of LMICs and other under-represented populations defined by ethnicity, sex, geography and minority groups within high-income countries remain largely excluded from PD research. The continuation of these disparities limits our knowledge of disease biology and restricts the applicability of advances in prevention, diagnosis and treatment, increasing inequity in global health. Substantial disparities persist across the PD research continuum, extending beyond resource limitations and encompassing epidemiology, environment, genetics, deep phenotyping and biomarkers, data integration and diversity-aware analytics, clinical trials and basic science. To repair structural diversity gaps that compromise validity and equity in PD research, we propose an ethically grounded, coordinated agenda that prioritizes increased funding and local capacity building in under-represented regions, the development and adoption of harmonized and context-adapted methods, sustained community engagement with cultural competence, the creation of collaborative research networks, and more inclusive editorial and regulatory policies. Moreover, because inequities in care and research commonly co-occur and are mutually reinforcing, PD research should advance alongside a worldwide commitment to minimum standards of care and access to treatment. This Perspective details diversity gaps across PD research, outlines priority actions to address them, and illustrates, through recent examples, how interventions along these axes can advance equity and representation in PD studies.

Indexed as

Biomedical ResearchGlobal HealthParkinson DiseaseDiversity, Equity, InclusionHumansWorkforce Diversity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.